Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2010-020737-50-GB
EUCTR2010-020737-50-GBActive, not recruitingNot Applicable

Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia

Merz Pharmaceuticals GmbH0 sites300 target enrollmentStarted: August 9, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
300
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Written informed consent obtained from the subject,
  • •2. Understanding of study procedures and willingness to abide by all procedures during the course of the study,
  • •3. Age =50 and =80,
  • •4. Subjective worsening of memory, concentration or attention problems for longer than 6 months,
  • •5. Woman of childbearing potential must be using a highly effective method of birth control,
  • •6. Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject,
  • •7.Patient Global Impression Severity” (PGI-S) score of =3,
  • •8. Experience of the memory, concentration or attention problems at least four times per week,
  • •9. MiniCog score of 3 or more
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Memory, concentration or attention problems interfere with basic daily activities, 2. Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia).
  • •3. Epilepsy or history of epileptic fits (inclusion questionnaire,
  • •4. Severe or acute mental illness (depression or anxiety),
  • •5. Significant systemic illness, such as cancer, kidney failure, severe hepatic impairment, uncontrolled diabetes,
  • •6. Heart attack, heart failure, arrhythmia or carotid stenosis within the last 6 months,
  • •7. History of stroke or transient ischaemic attacks within the last 6 months,
  • •8. Diagnosed pulmonary, gastrointestinal, hepatic, endocrine, untreated B12, TSH or folate deficiencies,
  • •9. Sleep apnea,
  • •10. Weight below 40kg or above 100kg,
  • •11. Previous or current treatment with memantine or participation in an investigational study with memantine,
  • •12. Con- current use of medication that could have effects on cognition ( seelist in the protocol, 8.3),
  • •13. Taking any medications that are contra-indicated in combination with memantine(see SmPC),
  • •14. Known or suspected history of alcoholism or drug abuse within the past 2 years, 15. Known hypersensitivity to the IP or reference, or any of their formulation ingredients,
  • •16. Subject who is imprisoned or is lawfully kept in an institution,
  • •17. Employee or direct relative of an employee of the CRO, the study site, or Merz, 18. Participation in a clinical study for an IP within the previous 90 days prior to visit 1,
  • •19. Previous participation in this clinical study
  • •20. Clinically significant laboratory results, which may indicate a cause for cognitive symptoms

Investigators

Similar Trials

Recruiting
Phase 4
Prospective, randomized, double-blind, placebo-controlled, multicenter clinical investigation to determine the clinical performance and safety of Luvos® Healing Earth in patients with histamine-mediated recurrent digestive symptoms.T78.1T62K58K59Other adverse food reactions, not elsewhere classifiedToxic effect of other noxious substances eaten as foodOther functional intestinal disordersIrritable bowel syndrome
DRKS00027333Heilerde-Gesellschaft Luvos Just GmbH % Co. KG114
Active, not recruiting
Phase 1
Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.MedDRA version: 18.1Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2012-005539-10-DEMerz Pharmaceuticals GmbH180
Active, not recruiting
Phase 1
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by stroke or traumatic brain injury.
EUCTR2018-001639-35-HUMerz Pharmaceuticals GmbH600
Active, not recruiting
Phase 1
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disability
EUCTR2013-004532-30-PLMerz Pharmaceuticals GmbH255
Active, not recruiting
Not Applicable
Prospective clinical trial, in which the test product (a cream containing 2% of Sertaconazol a known anti-mycotic ingredient) or the comparator product (cream without any active ingredient) are being dispatched randomly to the patients without that they or their physicians know which product they receive. Objective is to explore the anti-itch potential of the test product in atopic dermatitis as well as its safety and its local tolerability.Atopic Dermatitis
EUCTR2012-003954-95-DESpirig Pharma AG